VNDA
Vanda Pharmaceuticals Inc.NASDAQHealthcare$7.00-0.43%ClosedMarket Cap: $413.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.26
P/S
1.91
EV/EBITDA
-2.66
DCF Value
$-6.91
FCF Yield
-26.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.2%
Operating Margin
-71.6%
Net Margin
-102.0%
ROE
-49.2%
ROA
-45.1%
ROIC
-44.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $57.2M | 93.3% | $-40.4M | $-141.2M | $-2.39 | — |
| FY 2025 | $216.1M | 94.0% | $-151.2M | $-220.5M | $-3.74 | — |
| Q3 2025 | $56.3M | 94.7% | $-31.3M | $-22.6M | $-0.38 | — |
| Q2 2025 | $52.6M | 91.5% | $-38.5M | $-27.2M | $-0.46 | — |
| Q1 2025 | $50.0M | 93.0% | $-44.5M | $-29.5M | $-0.50 | — |
| Q4 2024 | $53.2M | 95.1% | $-10.3M | $-4.9M | $-0.08 | — |
| FY 2024 | $198.8M | 94.3% | $-40.7M | $-18.9M | $-0.32 | — |
| Q3 2024 | $47.7M | 94.6% | $-11.0M | $-5.3M | $-0.09 | — |
| Q2 2024 | $50.5M | 91.1% | $-10.1M | $-4.5M | $-0.08 | — |
| Q1 2024 | $47.5M | 88.5% | $-9.2M | $-4.1M | $-0.07 | — |
| Q4 2023 | $45.3M | 92.4% | $-7.1M | $-2.4M | $-0.04 | — |
| FY 2023 | $192.6M | 92.3% | $-14.0M | $2.5M | $0.04 | — |